{"content":"<li class=\"n-box-item date-title\" data-end=\"1504670399\" data-start=\"1504584000\" data-txt=\"Monday, December 23, 2019\">Tuesday, September  5, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3293717\" data-ts=\"1504662607\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDDY\" target=\"_blank\">GDDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293717-godaddy-discloses-20m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoDaddy discloses 20M-share secondary offering</a></h4><ul>     <li>GoDaddy (NYSE:<a href='https://seekingalpha.com/symbol/GDDY' title='GoDaddy Inc.'>GDDY</a>) <font color='red'>-3.2%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16931740-godaddy-inc-announces-proposed-sale-shares-common-stock\" target=\"_blank\">public offering</a> of ~20M common shares held by entities of Kohlberg Kravis Roberts, Silver Lake Partners, Technology Crossover Ventures, and YAM Special Holdings, which is owned by GDDY founder Bob Parsons; GDDY will not receive proceeds from the secondary offering.</li><li>GDDY also is offering 50K shares on its own, and plans to use the proceeds to pay the transaction  expenses incurred in the secondary offering and any remaining  proceeds for general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293717\" data-linked=\"GoDaddy discloses 20M-share secondary offering\" data-tweet=\"$GDDY - GoDaddy discloses 20M-share secondary offering https://seekingalpha.com/news/3293717-godaddy-discloses-20m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3293717-godaddy-discloses-20m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293715\" data-ts=\"1504655592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGTC\" target=\"_blank\">AGTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293715-applied-genetic-technologies-names-interim-chief-medical-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Genetic Technologies names interim chief medical officer</a></h4><ul>   <li>Biotech Applied Genetic Technologies (<a href=\"http://seekingalpha.com/symbol/AGTC\" target=\"_blank\">AGTC</a> <font color='red'>-4.3%</font>) has named Dr. Matthew Feinsod as its <a href=\"https://seekingalpha.com/pr/16931757-agtc-appoints-matthew-feinsod-m-d-interim-chief-medical-officer\" target=\"_blank\">interim chief medical officer</a>.</li>    <li>He replaces Dr. Michael Goldstein, who's leaving to pursue other opportunities.</li>    <li>Feinsod had joined the company in July 2014; he's a multiple patent holder in ophthalmology and has been a founder in a number of companies.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293715\" data-linked=\"Applied Genetic Technologies names interim chief medical officer\" data-tweet=\"$AGTC - Applied Genetic Technologies names interim chief medical officer https://seekingalpha.com/news/3293715-applied-genetic-technologies-names-interim-chief-medical-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3293715-applied-genetic-technologies-names-interim-chief-medical-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293709\" data-ts=\"1504651703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGM\" target=\"_blank\">MGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293709-mgmplus-1_6-executes-accretive-national-harbor-transaction-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MGM +1.6% as it executes accretive National Harbor transaction, buyback</a></h4><ul>   <li>MGM Resorts International (<a href=\"http://seekingalpha.com/symbol/MGM\" target=\"_blank\">MGM</a> <font color='red'>-0.2%</font>) and MGM Growth Properties (<a href=\"http://seekingalpha.com/symbol/MGP\" target=\"_blank\">MGP</a> <font color='green'>+0.1%</font>) have executed \"another <a href=\"https://seekingalpha.com/pr/16931604-mgm-resorts-international-mgm-growth-properties-llc-announce-transaction-mgm-national-harbor\" target=\"_blank\">accretive transaction</a>,\" around the MGM National Harbor casino resort in Maryland.</li>    <li>Shares of <a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> are <font color='green'>up 1.6%</font> after hours; <a href='https://seekingalpha.com/symbol/MGP' title='MGM Growth Properties LLC'>MGP</a> is <font color='red'>down 0.2%</font>.</li>    <li>A subsidiary of MGP will buy the long-term leasehold interest and real property improvements around National Harbor; MGM Resorts will lease and operate the property.</li>    <li>MGP is paying $1.1875B ($462.5M in cash, assuming $425M of National Harbor debt, and issuance of $300M worth of operating partnership units).</li>    <li>The rent payment to MGP will rise by $95M along the way. The sale is expected to close in Q4.</li>    <li>Also in MGM liquidity, MGM Resorts has announced a new <a href=\"https://seekingalpha.com/pr/16931622-mgm-resorts-international-announces-adoption-1_0-billion-share-repurchase-program\" target=\"_blank\">$1B buyback program</a> alongside the MGP transaction.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293709\" data-linked=\"MGM +1.6% as it executes accretive National Harbor transaction, buyback\" data-tweet=\"$MGM $MGM $MGP - MGM +1.6% as it executes accretive National Harbor transaction, buyback https://seekingalpha.com/news/3293709-mgmplus-1_6-executes-accretive-national-harbor-transaction-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3293709-mgmplus-1_6-executes-accretive-national-harbor-transaction-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293706\" data-ts=\"1504650128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GFF\" target=\"_blank\">GFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293706-griffon-to-buy-closetmaid-from-emerson-explore-options-for-clopay-plastic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Griffon to buy ClosetMaid from Emerson, explore options for Clopay Plastic</a></h4><ul>     <li>Griffon (NYSE:<a href='https://seekingalpha.com/symbol/GFF' title='Griffon Corporation'>GFF</a>)&nbsp;<font color='green'>+4.1%</font>&nbsp;AH after saying it plans to <a href=\"https://seekingalpha.com/pr/16931710-griffon-corporation-acquire-closetmaid-explore-strategic-alternatives-clopay-plastic-products\" target=\"_blank\">explore strategic alternatives</a> for its Clopay Plastic Products segment and agreeing to acquire Emerson's (NYSE:<a href='https://seekingalpha.com/symbol/EMR' title='Emerson Electric Co.'>EMR</a>) ClosetMaid business for $260M.</li>     <li>Griffon says it has received inquiries from \"qualified parties\" to buy Clopay Plastic Products, its maker of specialty plastic films for hygienic, health care and industrial products industries.</li>     <li>GFF expects the deal for ClosetMaid will be immediately accretive to cash flow and earnings; it sees ClosetMaid contributing $300M-$315M in revenue and $0.08-$0.10 in EPS in the first full year of operations.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293706\" data-linked=\"Griffon to buy ClosetMaid from Emerson, explore options for Clopay Plastic\" data-tweet=\"$GFF $GFF $EMR - Griffon to buy ClosetMaid from Emerson, explore options for Clopay Plastic https://seekingalpha.com/news/3293706-griffon-to-buy-closetmaid-from-emerson-explore-options-for-clopay-plastic?source=tweet\" data-url=\"https://seekingalpha.com/news/3293706-griffon-to-buy-closetmaid-from-emerson-explore-options-for-clopay-plastic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293700\" data-ts=\"1504647327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293700-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a> <font color='green'>+8.6%</font>. <a href='https://seekingalpha.com/symbol/EFII' title='Electronics for Imaging, Inc.'>EFII</a> <font color='green'>+8.5%</font>. <a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a> <font color='green'>+7.8%</font>. <a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+7.2%</font>. <a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a> <font color='green'>+5.1%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='red'>-5.1%</font>. <a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='red'>-3.0%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-2.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293700\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$COUP $EFII $DLTH - After Hours Gainers / Losers https://seekingalpha.com/news/3293700-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3293700-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293698\" data-ts=\"1504646020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTSL\" target=\"_blank\">MTSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293698-mer-telemanagement-sets-1-forminus-3-reverse-split-tomorrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mer Telemanagement sets 1-for-3 reverse split tomorrow</a></h4><ul>   <li>Mer Telemanagement (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a>) has set a <a href=\"https://seekingalpha.com/pr/16931558-mts-announces-effective-date-1-3-reverse-split\" target=\"_blank\">1-for-3 reverse stock split</a> to take effect at the commence of trading tomorrow.</li>    <li>The company closed <font color='red'>down 6%</font> to $0.60 today; it's working to lift its price above $1/share to satisfy Nasdaq minimums.</li>    <li>No fractional shares will be issued.</li>    <li>The reverse split will reduce outstanding ordinary shares from 9,367,566 to about 3,118,855.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293698\" data-linked=\"Mer Telemanagement sets 1-for-3 reverse split tomorrow\" data-tweet=\"$MTSL - Mer Telemanagement sets 1-for-3 reverse split tomorrow https://seekingalpha.com/news/3293698-mer-telemanagement-sets-1-forminus-3-reverse-split-tomorrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3293698-mer-telemanagement-sets-1-forminus-3-reverse-split-tomorrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293688\" data-ts=\"1504643864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293688-hewlett-packard-enterprise-shares-up-4_3-after-q3-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hewlett Packard Enterprise shares up 4.3% after Q3 beats</a></h4><ul><li>        Hewlett Packard Enterprise (NYSE:<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise'>HPE</a>) shares are&nbsp;<font color='green'>up 4.3%</font>&nbsp;aftermarket following Q3 EPS and revenue beats. The company did miss Q4 consensus estimates with a forecasted EPS range from $0.26 to $0.30, 11 cents lower than consensus on the higher end. FY17 EPS guidance was adjusted down to $1.36 to $1.40, four cents under consensus at the high end. The guidance changes reflected the spin-merger of the Software business, which completed this quarter.</li><li>               Segment revenue: Enterprise Group, $6.8B (+3% Y/Y); Software, $718M (-3%); Financial Services, $897M (+10%).&nbsp;&nbsp;</li><li>               Segment operating margin: Enterprise Group, 9.3%; Software, 24.9%; Financial Services, 7.8%.&nbsp;</li><li>               Key financials: Non-GAAP operating margin, 8.4% (-150 bps); net cash from operating activities, $891M; cash and equivalents, $7.8B.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/16931595-hpe-reports-fiscal-2017-third-quarter-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293666-hewlett-packard-enterprise-beats-0_04-beats-revenue\" target=\"_blank\">Hewlett Packard Enterprise beats by $0.04, beats on revenue</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293688\" data-linked=\"Hewlett Packard Enterprise shares up 4.3% after Q3 beats\" data-tweet=\"$HPE - Hewlett Packard Enterprise shares up 4.3% after Q3 beats https://seekingalpha.com/news/3293688-hewlett-packard-enterprise-shares-up-4_3-after-q3-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3293688-hewlett-packard-enterprise-shares-up-4_3-after-q3-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293683\" data-ts=\"1504643131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KTOS\" target=\"_blank\">KTOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293683-kratos-defense-to-launch-12_5m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kratos Defense to launch 12.5M-share offering</a></h4><ul>     <li>Kratos Defense and Security (NASDAQ:<a href='https://seekingalpha.com/symbol/KTOS' title='Kratos Defense & Security Solutions, Inc.'>KTOS</a>) <font color='red'>-5.1%</font>&nbsp;AH after commencing a <a href=\"https://seekingalpha.com/pr/16931609-kratos-defense-and-security-solutions-inc-announces-proposed-public-offering-common-stock\" target=\"_blank\">12.5M-share public offering</a>, with an underwriters option to purchase up to an additional 1.875M common shares.</li>     <li>KTOS says it plans to use the proceeds to position itself for projected growth from anticipated increased production via new programs and contracts, cut debt in order to reduce  its cost of capital and facilitate its long-term strategy, and for general corporate purposes, including potential acquisitions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293683\" data-linked=\"Kratos Defense to launch 12.5M-share offering\" data-tweet=\"$KTOS - Kratos Defense to launch 12.5M-share offering https://seekingalpha.com/news/3293683-kratos-defense-to-launch-12_5m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3293683-kratos-defense-to-launch-12_5m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293680\" data-ts=\"1504642752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KO\" target=\"_blank\">KO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293680-monster-beverage-up-3-on-takeover-chatter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monster Beverage up 3% on takeover chatter</a></h4><ul><li><a href=\"http://pipeline.thedeal.com/login/index.dl\" target=\"_blank\">According to The Deal</a>, Coca-Cola (NYSE:<a href='https://seekingalpha.com/symbol/KO' title='The Coca-Cola Company'>KO</a>) could be nearing a takeover of Monster Beverage (NASDAQ:<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a>).</li><li>MNST&nbsp;<font color='green'>+2.9%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3293680\" data-linked=\"Monster Beverage up 3% on takeover chatter\" data-tweet=\"$KO $KO $MNST - Monster Beverage up 3% on takeover chatter https://seekingalpha.com/news/3293680-monster-beverage-up-3-on-takeover-chatter?source=tweet\" data-url=\"https://seekingalpha.com/news/3293680-monster-beverage-up-3-on-takeover-chatter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293678\" data-ts=\"1504642674\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293678-dave-busters-entertainment-slips-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dave &amp; Buster&#39;s Entertainment slips after earnings</a></h4><ul>     <li>Comparable sales increased 1.6% for Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) in <a href=\"https://seekingalpha.com/pr/16931584-dave-and-buster-s-achieves-second-quarter-revenue-growth-14_9-percent-record-net-income\" target=\"_blank\">FQ2</a> to miss the consensus mark for a 2.6% gain.</li>     <li>EBITDA margin fell 70 bps to 22.8% of sales during the quarter.</li>     <li>\"We have opened eight stores and have an additional nine stores under construction. We now expect to open fourteen new stores this year, representing 15% unit growth, an increase over our previous guidance of twelve new stores,\" says CFO Brian Jenkins.</li>     <li>Looking ahead, Dave &amp; Busters expects FY18 revs of $1.16B to $1.17B vs $1.17B consensus.</li>     <li>Previously: <a href=\"https://seekingalpha.com/news/3293667-dave-and-busters-beats-0_02-misses-revenue\" target=\"_blank\">Dave &amp; Buster's beats by $0.02, misses on revenue</a> (Sept. 5)</li>     <li>PLAY&nbsp;<font color='red'>-6.05%</font>&nbsp;AH to $54.62.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293678\" data-linked=\"Dave &amp; Buster&#39;s Entertainment slips after earnings\" data-tweet=\"$PLAY - Dave &amp; Buster&#39;s Entertainment slips after earnings https://seekingalpha.com/news/3293678-dave-busters-entertainment-slips-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3293678-dave-busters-entertainment-slips-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293673\" data-ts=\"1504642496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSM\" target=\"_blank\">INSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293673-insmed-readies-250m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insmed readies $250M equity offering</a></h4><ul><li>Insmed (NASDAQ:<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a>) <a href=\"https://seekingalpha.com/pr/16931567-insmed-announces-proposed-public-offering-common-stock\" target=\"_blank\">announces </a>a $250M public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will fund the continued development of ALIS (amikacin liposome inhalation suspension) for patients with refractory nontuberculous mycobacteria lung disease, R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293673\" data-linked=\"Insmed readies $250M equity offering\" data-tweet=\"$INSM - Insmed readies $250M equity offering https://seekingalpha.com/news/3293673-insmed-readies-250m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3293673-insmed-readies-250m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293670\" data-ts=\"1504642314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASY\" target=\"_blank\">CASY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293670-store-sales-growth-for-caseys-general-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Same-store sales growth for Casey&#39;s General Stores</a></h4><ul> <li>Casey's General Stores (<a href='https://seekingalpha.com/symbol/CASY' title='Casey&#39;s General Stores, Inc.'>CASY</a> <font color='red'>-0.7%</font>) falls just short of analyst estimates with its FQ1 report.</li> <li>Same-store grocery /merchant sales were up 3.1% with an average margin of 31.9% vs. 31.6% a year ago.</li> <li>Same-store sales prepared food/fountain sales increased rose 3.7% with an average margin of 62.5% vs. 62.8% a year ago.</li> <li>Same-store gallons sold were up 1.7% with an average margin of $0.193 per gallon vs. $0.195 a year ago.</li> <li>\"Expansion activity for new store construction continues to increase as there are now 179 sites either under construction or under agreement,\" says CEO Terry Handley.</li><li>CASY&nbsp;<font color='green'>+0.31%</font>&nbsp;AH to $105.15.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293670\" data-linked=\"Same-store sales growth for Casey&#39;s General Stores\" data-tweet=\"$CASY - Same-store sales growth for Casey&#39;s General Stores https://seekingalpha.com/news/3293670-store-sales-growth-for-caseys-general-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3293670-store-sales-growth-for-caseys-general-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293659\" data-ts=\"1504641377\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293659-novo-slips-on-reported-12m-u-s-lawsuit-over-victoza-marketing-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novo slips on reported $12M U.S. lawsuit over Victoza marketing, shares down 1%</a></h4><ul><li>Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='red'>-0.7%</font>) is under pressure on reports that the U.S. Government has filed a lawsuit against the company seeking over $12M in damages. The Feds claim the company misbranded type 2 diabetes med <a href=\"https://www.victoza.com/?campaign=000722971&amp;utm_source=google&amp;utm_medium=cpc&amp;utm_term=victoza&amp;utm_campaign=Victoza+Brand+Expanded&amp;utm_content=General+Exact_-mkwid-suPAAwO7g_dc-pcrid-157889434553-pkw-victoza-pmt-e-&amp;gclid=CIrUiszpjtYCFdO3wAodn9kOmA\" target=\"_blank\">Victoza </a>(liraglutide) and failed to comply with risk evaluation requirements.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3293659\" data-linked=\"Novo slips on reported $12M U.S. lawsuit over Victoza marketing, shares down 1%\" data-tweet=\"$NVO - Novo slips on reported $12M U.S. lawsuit over Victoza marketing, shares down 1% https://seekingalpha.com/news/3293659-novo-slips-on-reported-12m-u-s-lawsuit-over-victoza-marketing-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3293659-novo-slips-on-reported-12m-u-s-lawsuit-over-victoza-marketing-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293658\" data-ts=\"1504641331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TECK\" target=\"_blank\">TECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293658-teck-resourcesminus-7-after-chinese-sovereign-wealth-fund-cuts-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teck Resources -7% after Chinese sovereign wealth fund cuts stake</a></h4><ul>     <li>Teck Resources (<a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-6.6%</font>) tumbles after announcing earlier that a Chinese sovereign wealth fund has <a href=\"https://seekingalpha.com/pr/16931259-cic-advises-partial-sale-teck-position\" target=\"_blank\">nearly halved its stake in the company</a>.</li>     <li>Teck says a subsidiary of China Investment Corp. had sold in a private transaction 42M Class B subordinate voting shares of the company, representing 7.36% of the outstanding B shares; CIC still indirectly holds 10.4% of the B shares.</li>     <li>Teck says CIC advised that the sale was part of the  ordinary course of its portfolio adjustment and that it would continue to hold the balance of its B shares as a long-term investor.</li><li>The sale comes after the Chinese government said late last month that it would emphasize policies &ldquo;to encourage Chinese  enterprises that invest overseas to spend more in their own country.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293658\" data-linked=\"Teck Resources -7% after Chinese sovereign wealth fund cuts stake\" data-tweet=\"$TECK - Teck Resources -7% after Chinese sovereign wealth fund cuts stake https://seekingalpha.com/news/3293658-teck-resourcesminus-7-after-chinese-sovereign-wealth-fund-cuts-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3293658-teck-resourcesminus-7-after-chinese-sovereign-wealth-fund-cuts-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293655\" data-ts=\"1504640228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293655-pulmatrix-receives-award-from-cf-foundation-to-support-development-of-pur1900-for-lung\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix receives award from CF Foundation to support development of PUR1900 for lung infection in CF and asthma patients; shares up 30%</a></h4><ul><li>Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+29.9%</font>) <a href=\"https://seekingalpha.com/pr/16931087-pulmatrix-receives-award-cystic-fibrosis-foundation-therapeutics-support-development-pur1900\" target=\"_blank\">announces </a>the receipt of a financial award from the Cystic Fibrosis Foundation that will support the development of PUR1900 for the treatment of a lung infection called allergic bronchopulmonary aspergillosis that strikes people with cystic fibrosis &#40;CF&#41;&nbsp;and asthma. The award will help fund nonclinical safety studies needed for the Phase 1/1b clinical trial that will commence next year. The specific amount of the award is not disclosed.</li><li>PUR1900, with Orphan Drug and QIDP status in the U.S., incorporates the company's dry powder&nbsp;<a href=\"http://pulmatrix.com/platform.html\" target=\"_blank\">iSPERSE&nbsp;</a>(inhaled small particles easily respirable and emitted) technology. The company says it overcomes the limitations of conventional lactose blend and metered dose inhaler technologies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293655\" data-linked=\"Pulmatrix receives award from CF Foundation to support development of PUR1900 for lung infection in CF and asthma patients; shares up 30%\" data-tweet=\"$PULM - Pulmatrix receives award from CF Foundation to support development of PUR1900 for lung infection in CF and asthma patients; shares up 30% https://seekingalpha.com/news/3293655-pulmatrix-receives-award-from-cf-foundation-to-support-development-of-pur1900-for-lung?source=tweet\" data-url=\"https://seekingalpha.com/news/3293655-pulmatrix-receives-award-from-cf-foundation-to-support-development-of-pur1900-for-lung\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293652\" data-ts=\"1504638925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293652-western-digital-wants-even-joint-venture-to-give-up-toshiba-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital wants even joint venture to give up Toshiba bid</a></h4><ul><li>        <a href=\"https://asia.nikkei.com/Spotlight/Toshiba-in-Turmoil/Western-Digital-offers-compromise-on-Toshiba-Memory-deal\" target=\"_blank\">Nikkei</a> has more details about the compromise where Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) would step out of the consortium bid for Toshiba&rsquo;s (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) chip unit in exchange for a larger part of the joint venture.</li><li>               Western Digital would want to buy some chip production capacity at fabs in Yokkaichi, Japan. The current joint venture in the area gives Toshiba a roughly 60-40 lead in ownership of production equipment and the output is allocated based on that ownership.&nbsp;</li><li>               Western Digital wants the split to move to 50-50.&nbsp;</li><li>               Last month, the companies butted heads when Toshiba said it planned to start a new fab in the area without Western Digital&rsquo;s participation.&nbsp;</li><li>               Western Digital still wants eventual voting rights but would not participate in the roughly $18.3B bid from the consortium including KKR, Innovation Network Corp. of Japan, and Development Bank of Japan. &nbsp;&nbsp;</li><li>Western Digital shares are&nbsp;<font color='red'>down 1.28%</font>. &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293449-reuters-western-digital-will-drop-chip-unit-bid-stronger-joint-venture\" target=\"_blank\">Reuters: Western Digital will drop chip unit bid for stronger joint venture</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293652\" data-linked=\"Western Digital wants even joint venture to give up Toshiba bid\" data-tweet=\"$WDC $WDC $TOSBF - Western Digital wants even joint venture to give up Toshiba bid https://seekingalpha.com/news/3293652-western-digital-wants-even-joint-venture-to-give-up-toshiba-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3293652-western-digital-wants-even-joint-venture-to-give-up-toshiba-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293650\" data-ts=\"1504638623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALK\" target=\"_blank\">ALK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293650-airline-stocks-fall-hurricane-irma-bearing-down-on-u-s\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Airline stocks fall with Hurricane Irma bearing down on U.S.</a></h4><ul> <li>Airline stocks fall as the approach of Hurricane Irma prompts flight cancellations to cities in the Caribbean. A large number of cancellations for flights to Florida is anticipated for later in the week.</li> <li>Decliners include Alaska Air Group (<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a> <font color='red'>-2.9%</font>), JetBlue (<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a> <font color='red'>-2.3%</font>), Southwest Airlines (<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a> <font color='red'>-2.1%</font>), Delta Airlines (<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a> <font color='red'>-3.1%</font>), American Airlines Group (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-2.6%</font>) and United Continental (<a href='https://seekingalpha.com/symbol/UAL' title='United Continental Holdings, Inc'>UAL</a> <font color='red'>-1.7%</font>).</li> <li>Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines'>SAVE</a> <font color='red'>-4.2%</font>)&nbsp;is also down sharply after lowering Q3 unit revenue guidance.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293559-hurricane-irma-major-threat-u-s\" target=\"_blank\">Hurricane Irma a major threat to U.S.</a> (Sept. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293650\" data-linked=\"Airline stocks fall with Hurricane Irma bearing down on U.S.\" data-tweet=\"$ALK $ALK $JBLU - Airline stocks fall with Hurricane Irma bearing down on U.S. https://seekingalpha.com/news/3293650-airline-stocks-fall-hurricane-irma-bearing-down-on-u-s?source=tweet\" data-url=\"https://seekingalpha.com/news/3293650-airline-stocks-fall-hurricane-irma-bearing-down-on-u-s\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293645\" data-ts=\"1504637720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293645-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PCOM' title='Points International, Ltd.'>PCOM</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/XPLR' title='Xplore Technologies Corp.'>XPLR</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EXFO' title='EXFO Inc.'>EXFO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/QNST' title='QuinStreet, Inc.'>QNST</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KT' title='KT Corporation'>KT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HLIT' title='Harmonic Inc.'>HLIT</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293645\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$PCOM $NH $XPLR - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3293645-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293645-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293641\" data-ts=\"1504636081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293641-barclays-apple-smart-home-products-build-loyalty-not-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays: Apple smart home products build loyalty not revenue</a></h4><ul><li>        Barclays <a href=\"https://9to5mac.com/2017/09/05/barclays-apple-homekit-siri/\" target=\"_blank\">thinks</a> Apple&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) smart home products won&rsquo;t drive sales but will drive customer loyalty.</li><li>               The note from analysts Mark Moskowitz, Daniel Gaide, and Chang Liu says Apple has an advantage over Amazon in that Siri is available on more than 700M devices compared to 20M for Echo. The iPhone makes a &ldquo;natural control panel&rdquo; for a smart home &ldquo;due to its user-friendly interface and constant presence with the user.&rdquo;&nbsp;</li><li>               The analysts are skeptical Apple can leverage the smart home usage into material revenue in the near-term because they expect December&rsquo;s HomePod smart speaker to be &ldquo;an ancillary offering.&rdquo;</li><li>               On the positive side, the analysts say that customers who do use the iPhone for a connected home won&rsquo;t want to switch platforms in the future.&nbsp;</li><li>               Price target is $146, below the current trading price of about $161 as Barclays expects a soft iPhone 8 launch.&nbsp;</li><li>Apple shares are&nbsp;<font color='red'>down 1.18%</font>. &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293598-bernstein-outlines-apple-rally-continue-launch-event\" target=\"_blank\">Bernstein outlines how Apple rally could continue after launch event</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293641\" data-linked=\"Barclays: Apple smart home products build loyalty not revenue\" data-tweet=\"$AAPL - Barclays: Apple smart home products build loyalty not revenue https://seekingalpha.com/news/3293641-barclays-apple-smart-home-products-build-loyalty-not-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3293641-barclays-apple-smart-home-products-build-loyalty-not-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293637\" data-ts=\"1504634446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293637-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PZG' title='Paramount Gold Nevada Corp.'>PZG</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ERN' title='Erin Energy Corp.'>ERN</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ALDW' title='Alon USA Partners'>ALDW</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293637\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$PZG $ERN $YUMA - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3293637-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293637-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293636\" data-ts=\"1504634342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CODX\" target=\"_blank\">CODX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293636-co-diagnostics-inks-deal-for-test-use-in-india-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Co-Diagnostics inks deal for test use in India; shares ahead 4%</a></h4><ul><li>Co-Diagnostics (<a href='https://seekingalpha.com/symbol/CODX' title='Co-Diagnostics'>CODX</a> <font color='green'>+3.9%</font>) enters into an <a href=\"https://seekingalpha.com/pr/16931051-co-diagnostics-inc-sign-purchase-agreement-medcis-pathlabs\" target=\"_blank\">agreement </a>with MEDCIS Pathlabs India Pvt. Ltd. enabling the use of its diagnostic tests throughout India. MEDCIS and its associates will initially purchase 36K of the company's tests for hepatitis B, C HIV and HPV.</li><li>The tests will be manufactured and branded by CoSara Diagnostics, Co-Diagnostics' manufacturing joint venture, who will also be &nbsp;responsible for all regulatory approvals.</li><li>The deal includes future Co-Diagnostics products, including a blood bank panel.</li><li>CEO Dwight Egan says the partnership has the potential to be the company's largest revenue generator to date.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293636\" data-linked=\"Co-Diagnostics inks deal for test use in India; shares ahead 4%\" data-tweet=\"$CODX - Co-Diagnostics inks deal for test use in India; shares ahead 4% https://seekingalpha.com/news/3293636-co-diagnostics-inks-deal-for-test-use-in-india-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3293636-co-diagnostics-inks-deal-for-test-use-in-india-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293633\" data-ts=\"1504633430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLTH\" target=\"_blank\">HLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293633-nobilis-health-houston-area-surgery-volume-back-on-track-after-harvey-flooding-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nobilis Health Houston-area surgery volume back on track after Harvey flooding; shares up 2%</a></h4><ul><li>Nobilis Health (<a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a> <font color='green'>+1.7%</font>) <a href=\"https://seekingalpha.com/pr/16930359-nobilis-health-corp-issues-hurricane-harvey-update\" target=\"_blank\">announces </a>that its normal case volume of surgeries in the Houston area is resuming today thanks to around-the-clock efforts to repair/remediate operating rooms damaged by flooding from Hurricane Harvey.</li><li>The company says 16 of its 21 operating rooms at 10 sites in the area are back in service. Some cases have been moved to other sites in the interim.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293633\" data-linked=\"Nobilis Health Houston-area surgery volume back on track after Harvey flooding; shares up 2%\" data-tweet=\"$HLTH - Nobilis Health Houston-area surgery volume back on track after Harvey flooding; shares up 2% https://seekingalpha.com/news/3293633-nobilis-health-houston-area-surgery-volume-back-on-track-after-harvey-flooding-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3293633-nobilis-health-houston-area-surgery-volume-back-on-track-after-harvey-flooding-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293628\" data-ts=\"1504632397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UVE\" target=\"_blank\">UVE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293628-p-and-c-insurers-slide-in-front-of-irma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">P&amp;C insurers slide in front of Irma</a></h4><ul><li>Those with heavy Florida exposure are being hit hardest - Universal Insurance (<a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-16.9%</font>), Federated National (<a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='red'>-15.3%</font>), Heritage Insurance (<a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='red'>-14.2%</font>), United Insurance (<a href='https://seekingalpha.com/symbol/UIHC' title='United Insurance Holdings Corp.'>UIHC</a> <font color='red'>-9%</font>), HCI Group (<a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-14.7%</font>) to name five.</li><li>Travelers (<a href='https://seekingalpha.com/symbol/TRV' title='The Travelers Companies, Inc.'>TRV</a> <font color='red'>-3%</font>), Allstate (<a href='https://seekingalpha.com/symbol/ALL' title='Allstate Corporation'>ALL</a> <font color='red'>-2.7%</font>), Chubb (<a href='https://seekingalpha.com/symbol/CB' title='Chubb Ltd'>CB</a> <font color='red'>-1.9%</font>), Cincinnati Financial (<a href='https://seekingalpha.com/symbol/CINF' title='Cincinnati Financial Corporation'>CINF</a> <font color='red'>-2.6%</font>), W.R. Berkley (<a href='https://seekingalpha.com/symbol/WRB' title='W.R. Berkley Corporation'>WRB</a> <font color='red'>-3.9%</font>), Progressive (<a href='https://seekingalpha.com/symbol/PGR' title='Progressive Corporation'>PGR</a> <font color='red'>-3%</font>), 1347 Property (<a href='https://seekingalpha.com/symbol/PIH' title='1347 Property Insurance Holdings, Inc.'>PIH</a> <font color='red'>-2%</font>).</li><li>Checking reinsurers: Everest Re (<a href='https://seekingalpha.com/symbol/RE' title='Everest Re Group Ltd.'>RE</a> <font color='red'>-6%</font>), RenaissanceRe (<a href='https://seekingalpha.com/symbol/RNR' title='RenaissanceRe Holdings Ltd.'>RNR</a> <font color='red'>-6.2%</font>), Aspen (<a href='https://seekingalpha.com/symbol/AHL' title='Aspen Insurance Holdings Limited'>AHL</a> <font color='red'>-7%</font>), Axis Capital (<a href='https://seekingalpha.com/symbol/AXS' title='Axis Capital Holdings Limited'>AXS</a> <font color='red'>-5.7%</font>), XL Group (<a href='https://seekingalpha.com/symbol/XL' title='XL Group plc'>XL</a> <font color='red'>-6%</font>), Reinsurance Group of America (<a href='https://seekingalpha.com/symbol/RGA' title='Reinsurance Group of America, Incorporated'>RGA</a> <font color='red'>-2.9%</font>)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293559-hurricane-irma-major-threat-u-s\" target=\"_blank\">Hurricane Irma a major threat to U.S.</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293628\" data-linked=\"P&amp;C insurers slide in front of Irma\" data-tweet=\"$UVE $UVE $FNHC - P&amp;C insurers slide in front of Irma https://seekingalpha.com/news/3293628-p-and-c-insurers-slide-in-front-of-irma?source=tweet\" data-url=\"https://seekingalpha.com/news/3293628-p-and-c-insurers-slide-in-front-of-irma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293625\" data-ts=\"1504631533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293625-ligand-pharmas-t2d-candidate-lgdminus-6972-successful-in-mid-stage-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ligand Pharma&#39;s T2D candidate LGD-6972 successful in mid-stage study; shares up 1%</a></h4><ul><li>Thinly traded Ligand Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color='green'>+1.1%</font>) bucks the market's foul mood, albeit on light turnover of only 147K shares, after it <a href=\"https://seekingalpha.com/pr/16930587-ligand-announces-top-line-results-phase-2-study-lgdminus-6972-patients-type-2-diabetes\" target=\"_blank\">announced </a>positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02851849?term=LGD-6972&amp;spons=ligand+pharmaceuticals&amp;rank=4\" target=\"_blank\">Phase 2 clinical trial</a> assessing LGD-6972 for the treatment of people with type 2 diabetes (T2D).</li><li>The study met its primary endpoint of a statistically significant change from baseline in hemoglobin A1c (HbA1c) after 12 weeks of treatment at all doses tested, specifically reductions of 0.90%, 0.92% and 1.20% for the 5 mg, 10 mg and 15 mg doses, respectively (p&lt;0.0001).</li><li>LGD-6972, a small molecule glucagon receptor antagonist, was safe and well-tolerated.</li><li>More detailed results will be submitted for presentation at future medical conferences and for publication.</li><li>Clinical development is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293625\" data-linked=\"Ligand Pharma&#39;s T2D candidate LGD-6972 successful in mid-stage study; shares up 1%\" data-tweet=\"$LGND - Ligand Pharma&#39;s T2D candidate LGD-6972 successful in mid-stage study; shares up 1% https://seekingalpha.com/news/3293625-ligand-pharmas-t2d-candidate-lgdminus-6972-successful-in-mid-stage-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3293625-ligand-pharmas-t2d-candidate-lgdminus-6972-successful-in-mid-stage-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293624\" data-ts=\"1504631426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLO\" target=\"_blank\">VLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293624-valero-seeks-waiver-to-colonial-pipeline-fuel-specifications-after-harvey\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valero seeks waiver to Colonial Pipeline fuel specifications after Harvey</a></h4><ul>     <li>Valero Energy (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-2.7%</font>) asks the FERC to allow or direct Colonial Pipeline to l<a href=\"http://www.reuters.com/article/us-storm-harvey-valero-energy-colonial-c/valero-seeks-ferc-waiver-to-colonial-pipeline-fuel-specifications-after-harvey-idUSKCN1BG2FR\" target=\"_blank\">ift gasoline grade requirements</a> in the wake of Hurricane Harvey.</li>     <li>The waivers would allow VLO and other Gulf Coast refiners to resume shipments without \"undue and unreasonable\" hindrances, VLO says in a filing with the regulator.</li>     <li>VLO says Colonial's move to restrict the grades of gasoline flowing on its system is inconsistent with the intended effect of the EPA's emergency fuel waivers for 38 states and D.C. after Harvey shut refineries and gasoline prices spiked.</li>     <li>The EPA's waiver, in place until Sept. 15, allows gasoline with higher volatility to be sold during the temporary emergency period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293624\" data-linked=\"Valero seeks waiver to Colonial Pipeline fuel specifications after Harvey\" data-tweet=\"$VLO - Valero seeks waiver to Colonial Pipeline fuel specifications after Harvey https://seekingalpha.com/news/3293624-valero-seeks-waiver-to-colonial-pipeline-fuel-specifications-after-harvey?source=tweet\" data-url=\"https://seekingalpha.com/news/3293624-valero-seeks-waiver-to-colonial-pipeline-fuel-specifications-after-harvey\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293622\" data-ts=\"1504630760\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293622-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/FMAO' title='Farmers & Merchants Bancorp Inc.'>FMAO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293622\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$SGLB $FMAO $OXBR - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3293622-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293622-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293621\" data-ts=\"1504630759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTEN\" target=\"_blank\">PTEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293621-patterson-uti-upgraded-j-p-morgan-following-recent-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Patterson-UTI upgraded at J.P. Morgan following recent weakness</a></h4><ul>     <li>Patterson-UTI Energy (<a href='https://seekingalpha.com/symbol/PTEN' title='Patterson-UTI Energy, Inc.'>PTEN</a> <font color='green'>+5.8%</font>) is <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10013913/patterson-uti-energy-recent-weakness-reveals-relative-o\" target=\"_blank\">upgraded</a> to Overweight from Neutral with a $24 price target at J.P. Morgan, which says the stock's 26% selloff since mid-July has created a buying opportunity.</li>     <li>JPM says PTEN shares currently trade at 5.5x the firm's 2018 EBITDA, which makes it the cheapest among all land drillers it covers, and investors should take advantage of the \"dislocation in valuation\" as the stock's poor performance does not square with the company's solid exposure to the best volume and pricing story in the North American frac industry.</li><li>Finally, looking to 2018, PTEN&nbsp;is expected to reactivate three more fleets during H2 that will be accretive to its margins and push its utilization rate above 80%, the firm adds.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293621\" data-linked=\"Patterson-UTI upgraded at J.P. Morgan following recent weakness\" data-tweet=\"$PTEN - Patterson-UTI upgraded at J.P. Morgan following recent weakness https://seekingalpha.com/news/3293621-patterson-uti-upgraded-j-p-morgan-following-recent-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3293621-patterson-uti-upgraded-j-p-morgan-following-recent-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293618\" data-ts=\"1504630266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLE\" target=\"_blank\">XLE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293618-market-losses-extend-to-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Market losses extend to 1%</a></h4><ul><li>Declines are building as the day moves along, with the S&amp;P 500 now<font color='red'> lower by 1%</font>, the Dow&nbsp;<font color='red'>1.1%</font>, and the Nasdaq&nbsp;<font color='red'>1.3%</font>.</li><li>The <a href=\"https://seekingalpha.com/news/3293582-financials-lead-markets-lower-rates-slide\" target=\"_blank\">banks are leading</a> on the downside, but an outlier to the upside is energy (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color='green'>+0.1%</font>). Helping is a&nbsp;<font color='green'>3% surge</font>&nbsp;in oil as refineries <a href=\"https://seekingalpha.com/news/3293486-crude-oil-moves-higher-gasoline-prices-crushed\" target=\"_blank\">come back online</a> post-Harvey.</li><li>Surely hurting the broader market today is the next hurricane. It's still early, but Irma could be as, or even more catastrophic than Harvey. Florida has declared a state of emergency.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293618\" data-linked=\"Market losses extend to 1%\" data-tweet=\"$XLE - Market losses extend to 1% https://seekingalpha.com/news/3293618-market-losses-extend-to-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3293618-market-losses-extend-to-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293615\" data-ts=\"1504629791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293615-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='green'>+102%</font>. <a href='https://seekingalpha.com/symbol/CDZI' title='Cadiz, Inc.'>CDZI</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PCOM' title='Points International, Ltd.'>PCOM</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/JYNT' title='The Joint Corp.'>JYNT</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/UVE' title='Universal Insurance Holdings, Inc'>UVE</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/LINU-OLD' title='LiNiu Technology Group'>LINU-OLD</a> <font color='red'>-11%</font>. COOL <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293615\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$INSM $CDZI $XOMA - Midday Gainers / Losers https://seekingalpha.com/news/3293615-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3293615-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293613\" data-ts=\"1504629700\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293613-mimedx-bullish-on-q3-sees-revenues-above-guidance-and-over-80m-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx bullish on Q3, sees revenues above guidance and over $80M; shares up 3%</a></h4><ul><li>MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a> <font color='green'>+3.1%</font>) says it <a href=\"https://seekingalpha.com/pr/16931330-mimedx-announces-expectations-third-quarter-revenue-exceed-80-million-surpass-previous\" target=\"_blank\">expects to book</a> in excess of $80M in sales this quarter, the high end of its revenue guidance.</li><li>CEO Parker H. Petit says, \"Revenue for the first two months of the third quarter has been very strong, and we expect an equally strong revenue performance in September and beyond.&nbsp; We previously guided to a third quarter revenue range of $79 million to $80 million, and based on the strength of our July and August revenue performance, we are now in a position to announce that we expect to exceed $80 million in revenue for the third quarter of 2017. &nbsp;We realize that much of the medical community in the areas impacted by Hurricane Harvey's devastation will take some time before they are back to their pre-Harvey levels of wound care and surgical procedures. &nbsp;However, we expect the impact of these temporary lesser levels of procedures in the areas devastated by Harvey will be offset by stronger than anticipated performance in other parts of the country.\"</li><li>The company adds that it is confident in its ability to meet/exceed its 2017 revenue guidance of $309M - 311M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293613\" data-linked=\"MiMedx bullish on Q3, sees revenues above guidance and over $80M; shares up 3%\" data-tweet=\"$MDXG - MiMedx bullish on Q3, sees revenues above guidance and over $80M; shares up 3% https://seekingalpha.com/news/3293613-mimedx-bullish-on-q3-sees-revenues-above-guidance-and-over-80m-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3293613-mimedx-bullish-on-q3-sees-revenues-above-guidance-and-over-80m-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293610\" data-ts=\"1504628660\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MPC\" target=\"_blank\">MPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293610-marathon-petroleum-to-keep-speedway-gains-elliotts-support\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marathon Petroleum to keep Speedway, gains Elliott&#39;s support</a></h4><ul>     <li>Marathon Petroleum (<a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-4.9%</font>) says it will <a href=\"http://ir.marathonpetroleum.com/phoenix.zhtml?c=246631&amp;p=irol-newsArticle&amp;ID=2298215\" target=\"_blank\">keep its Speedway retail business</a>, a decision backed by activist investor Elliott Management, which had previously pushed the company to separate the business.</li>     <li>MPC&rsquo;s decision to maintain the business represents a unique case where a company has opted against an Elliott demand, yet still managed to <a href=\"http://www.reuters.com/article/us-marathon-pete-speedway/marathon-petroleum-gains-elliotts-support-to-keep-speedway-idUSKCN1BG2D8\" target=\"_blank\">earn the hedge fund&rsquo;s support</a>.</li>     <li>MPC says a Speedway spinoff would have required at least $2.5B of debt reduction and an additional $1B of cash to manage leverage targets and its investment grade rating.</li>     <li>MPC also says it has returned $1.55B to shareholders in H1 and plans to repurchase $1B of additional shares by year-end 2017.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293610\" data-linked=\"Marathon Petroleum to keep Speedway, gains Elliott&#39;s support\" data-tweet=\"$MPC - Marathon Petroleum to keep Speedway, gains Elliott&#39;s support https://seekingalpha.com/news/3293610-marathon-petroleum-to-keep-speedway-gains-elliotts-support?source=tweet\" data-url=\"https://seekingalpha.com/news/3293610-marathon-petroleum-to-keep-speedway-gains-elliotts-support\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293604\" data-ts=\"1504627881\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293604-consumer-top-gainers-losers-of-12-10-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:10 pm</a></h4><ul>    <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/LBIX-OLD' title='Leading Brands Inc'>LBIX-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293604\" data-linked=\"Consumer - Top Gainers / Losers as of 12:10 pm\" data-tweet=\"$WATT $LBIX-OLD $TIS - Consumer - Top Gainers / Losers as of 12:10 pm https://seekingalpha.com/news/3293604-consumer-top-gainers-losers-of-12-10-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3293604-consumer-top-gainers-losers-of-12-10-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293603\" data-ts=\"1504627794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PPC\" target=\"_blank\">PPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293603-vertical-pulls-back-on-pilgrims-pride-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vertical pulls back on Pilgrim&#39;s Pride expectations</a></h4><ul> <li>Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='red'>-2.7%</font>) trades lower after <a href=\"http://www.vertgrp.com/index.php/research\" target=\"_blank\">Vertical Group</a> warns on the impact of trade issues with China and South Korea amid the North Korea situation. The result could be a hit to pricing in the U.S. due to oversupply.</li> <li>Vertical lowers its rating on Pilgrim's to Hold from Buy and takes its price target to $32.</li><li>Shares of Pilgrim's Pride are up 51% YTD.</li> <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293603\" data-linked=\"Vertical pulls back on Pilgrim&#39;s Pride expectations\" data-tweet=\"$PPC - Vertical pulls back on Pilgrim&#39;s Pride expectations https://seekingalpha.com/news/3293603-vertical-pulls-back-on-pilgrims-pride-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3293603-vertical-pulls-back-on-pilgrims-pride-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293602\" data-ts=\"1504627672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNK\" target=\"_blank\">MNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293602-mallinckrodt-targeted-missouri-ag-over-opioid-marketing-shares-down-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mallinckrodt targeted by Missouri AG over opioid marketing; shares down 14%</a></h4><ul><li>The market's selloff notwithstanding, Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-13.9%</font>) is getting some rough treatment on double normal volume. Last week, Missouri Attorney General Josh Hawley <a href=\"http://www.missouribusinessalert.com/industries/87279/2017/08/31/hawley-extends-opioid-probe-to-7-more-companies-includes-mallinckrodt/\" target=\"_blank\">announced </a>a widening of his investigation into the marketing activities of certain opioid manufacturers. Targeted companies include Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-1.3%</font>), Depomed (DEPO <font color='green'>+0.5%</font>), Insys Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='green'>+0.9%</font>), Mylan (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='green'>+0.2%</font>), Pfizer (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-0.5%</font>) and Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-2.6%</font>).</li><li>Hawley sued Endo Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='red'>-4.1%</font>), privately held Purdue Pharma and J&amp;J's Janssen Pharmaceuticals (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='red'>-0.6%</font>) in June accusing them of violating state consumer protection laws by misleading doctors and consumers about the risks of taking opioids.</li><li>SA Contributor Shock Exchange has just <a href=\"https://seekingalpha.com/article/4104114-another-opioid-investigation-mallinckrodt\" target=\"_blank\">published </a>a new article on the issue that should be of interest to MNK investors.</li><li><strong>Update</strong>: Bloomberg <a href=\"https://www.streetinsider.com/Corporate+News/Mallinckrodt+%28MNK%29+Loses+Court+Ruling+in+Bid+to+Block+Inomax+Generic+-+Bloomberg/13264467.html\" target=\"_blank\">reported </a>earlier today that the company lost its bid to block the entry of a generic competitor (Praxair) to Inomax (nitric oxide), which accounted for over 15% ($125.5M) of the company's Q2 sales of $824.5M. A federal judge in Delaware <a href=\"http://www.stltoday.com/business/local/u-s-judge-invalidates-mallinckrodt-patents-on-respiratory-treatment/article_8601f727-0980-5e43-bc7f-3c7762eaa368.html\" target=\"_blank\">invalidated </a>patents covering Inomax. The company plans to appeal the decision, adding that it has regulatory exclusivity until October 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293602\" data-linked=\"Mallinckrodt targeted by Missouri AG over opioid marketing; shares down 14%\" data-tweet=\"$MNK $MNK $AGN - Mallinckrodt targeted by Missouri AG over opioid marketing; shares down 14% https://seekingalpha.com/news/3293602-mallinckrodt-targeted-missouri-ag-over-opioid-marketing-shares-down-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3293602-mallinckrodt-targeted-missouri-ag-over-opioid-marketing-shares-down-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293582\" data-ts=\"1504624497\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293582-financials-lead-markets-lower-rates-slide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials lead markets lower as rates slide</a></h4><ul><li>The <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/KRE' title='SPDR S&P Regional Banking ETF'>KRE</a>, and <a href='https://seekingalpha.com/symbol/KBE' title='SPDR S&P Bank ETF'>KBE</a> are all&nbsp;<font color='red'>down about 1.5%</font>, more than tripling the S&amp;P 500's modest decline today.</li><li>A ratcheting up in North Korea tensions and a Category 5 hurricane taking aim at Florida are teaming up as excuses to sell. Financials in particular <a href=\"https://seekingalpha.com/news/3293568-10-year-treasury-yield-tumbles-2_10-percent\" target=\"_blank\">are eyeing a tumble</a> in interest rates - the 10-year yield down a full eight basis points to 2.087%. On the short-end, traders have shaved to zero the odds of a rate hike this month, and are pricing in just a one-in-three chance of another move at any point this year.</li><li>Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-2.5%</font>), Goldman Sachs (<a href='https://seekingalpha.com/symbol/GS' title='Goldman Sachs Group Inc.'>GS</a> <font color='red'>-3.2%</font>), JPMorgan (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-2.2%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-2.5%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-2%</font>), SunTrust (<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a> <font color='red'>-1.9%</font>), Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-1.9%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293582\" data-linked=\"Financials lead markets lower as rates slide\" data-tweet=\"$BAC $XLF $KRE - Financials lead markets lower as rates slide https://seekingalpha.com/news/3293582-financials-lead-markets-lower-rates-slide?source=tweet\" data-url=\"https://seekingalpha.com/news/3293582-financials-lead-markets-lower-rates-slide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293576\" data-ts=\"1504623780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIGO\" target=\"_blank\">TIGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293576-idt-guatemalas-tigo-sign-reciprocal-service-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IDT, Guatemala&#39;s Tigo sign reciprocal service deal</a></h4><ul>   <li>IDT (<a href=\"http://seekingalpha.com/symbol/IDT\" target=\"_blank\">IDT</a> <font color='green'>+0.8%</font>) and Comcel Guatemala (a k a Tigo, part-owned by MIICF <font color='green'>+2.3%</font>) have sigend a <a href=\"https://seekingalpha.com/pr/16930723-idt-tigo-guatemala-sign-reciprocal-services-agreement\" target=\"_blank\">reciprocal services deal</a> that will allow for calls be completed in Tigo's Guatemalan network.</li>    <li>The arrangement will increase wholesale minute volumes through the country, and \"greatly improve IDT's competitive position in Guatemala as a service provider of international voice calls, both inbound and outbound,\" says IDT Telecom CEO Bill Pereira.</li>    <li>Guatemalans in North America and Europe will benefit by use of IDT's BOSS Revolution calling service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293576\" data-linked=\"IDT, Guatemala&#39;s Tigo sign reciprocal service deal\" data-tweet=\"$TIGO $TIGO $IDT - IDT, Guatemala&#39;s Tigo sign reciprocal service deal https://seekingalpha.com/news/3293576-idt-guatemalas-tigo-sign-reciprocal-service-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3293576-idt-guatemalas-tigo-sign-reciprocal-service-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293546\" data-ts=\"1504623665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293546-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='green'>+108%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MZOR' title='Mazor Robotics Ltd.'>MZOR</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293546\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$INSM $XOMA $INFI - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3293546-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3293546-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293574\" data-ts=\"1504623499\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSN\" target=\"_blank\">ALSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293574-allison-transmission-slides-on-deutsche-bank-caution\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allison Transmission slides on Deutsche Bank caution</a></h4><ul> <li>Allison Transmission Holdings (<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='red'>-2.7%</font>) trades lower after Deutsche Bank warns on the risk to the company from the global push to electrification.</li> <li>Deutsche Bank moves to a Sell rating on Allison from Hold due to the long-term risk seen for the company.</li> <li>Shares of Allison Transmission are down 12% over the last 90 days.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292710-piper-jaffray-warns-ev-impact-allison-transmission\" target=\"_blank\">Piper Jaffray warns of EV impact on Allison Transmission</a> (Aug. 30)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293574\" data-linked=\"Allison Transmission slides on Deutsche Bank caution\" data-tweet=\"$ALSN - Allison Transmission slides on Deutsche Bank caution https://seekingalpha.com/news/3293574-allison-transmission-slides-on-deutsche-bank-caution?source=tweet\" data-url=\"https://seekingalpha.com/news/3293574-allison-transmission-slides-on-deutsche-bank-caution\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293573\" data-ts=\"1504623356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STX\" target=\"_blank\">STX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293573-seagate-shares-up-following-valueact-morgan-stanley-investment-disclosure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seagate shares up following ValueAct, Morgan Stanley investment disclosure</a></h4><ul><li>        Seagate Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a>) riding&nbsp;<font color='green'>up 4.28%</font>&nbsp;following Friday&rsquo;s aftermarket <a href=\"https://www.reuters.com/article/brief-valueact-capital-master-fund-says/brief-valueact-capital-master-fund-says-on-aug-31-entered-into-a-stock-purchase-agreement-with-morgan-stanley-related-to-seagate-technology-idUSFWN1LI0PX\" target=\"_blank\">disclosure</a> that ValueAct Capital entered into a stock purchase agreement with Morgan Stanley for Seagate.</li><li>               Morgan Stanley will buy up to 6M Seagate shares for the account of ValueAct with the purchases occurring between September 1 and October 31.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288702-cleveland-research-says-dram-nand-trends-will-continue-next-year\" target=\"_blank\">Cleveland Research says DRAM / NAND trends will continue next year</a> (Aug. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293573\" data-linked=\"Seagate shares up following ValueAct, Morgan Stanley investment disclosure\" data-tweet=\"$STX - Seagate shares up following ValueAct, Morgan Stanley investment disclosure https://seekingalpha.com/news/3293573-seagate-shares-up-following-valueact-morgan-stanley-investment-disclosure?source=tweet\" data-url=\"https://seekingalpha.com/news/3293573-seagate-shares-up-following-valueact-morgan-stanley-investment-disclosure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293569\" data-ts=\"1504622874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XTNT\" target=\"_blank\">XTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293569-fda-clears-xtants-irix-spinal-fusion-device-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Xtant&#39;s IRIX-A spinal fusion device; shares up 10%</a></h4><ul><li>The FDA <a href=\"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K171567\" target=\"_blank\">grants </a>510(k) clearance for Xtant Medical's (<a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a> <font color='green'>+10.4%</font>) <a href=\"https://xtantmedical.com/product/irix-a/\" target=\"_blank\">IRIX-A</a> Lumbar Integrated Fusion System, designed for anterior spinal fusion procedures. The device consists of integrated titanium ring surrounded by an outer PEEK (polyetheretherketone) ring and three screws.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293569\" data-linked=\"FDA clears Xtant&#39;s IRIX-A spinal fusion device; shares up 10%\" data-tweet=\"$XTNT - FDA clears Xtant&#39;s IRIX-A spinal fusion device; shares up 10% https://seekingalpha.com/news/3293569-fda-clears-xtants-irix-spinal-fusion-device-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3293569-fda-clears-xtants-irix-spinal-fusion-device-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293568\" data-ts=\"1504622781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293568-10-year-treasury-yield-tumbles-below-2_10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">10-year Treasury yield tumbles below 2.10%</a></h4><ul><li>The ratcheting up of tensions between the U.S. and North Korea makes for a good excuse, but there was also <a href=\"https://seekingalpha.com/news/3293491-feds-brainard-board-another-rate-hike\" target=\"_blank\">a highly dovish talk</a> from Fed Governor Brainard this morning. Set to speak later are other Fed doves - Minneapolis' Neel Kaskkari and Dallas' Robert Kaplan.</li><li>With the doves making a lot of noise of late, the betting is that Fed boss Yellen moves ahead with a compromise this month - no rate hike, but the beginning of a paring of the Fed balance sheet. Thirty-day Fed Funds futures are pricing in zero chance of a rate hike in two weeks, and just a one-in-three chance of another move this year.</li><li>The 10-year Treasury yield is down seven basis points to 2.09% - sliding below 2.10% for the first time since shortly after the November election.</li><li><a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>&nbsp;<font color='green'>+1.25%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>&nbsp;<font color='red'>-2.5%</font></li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Government Bond Index ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/TLO' title='SPDR Barclays Long Term Treasury ETF'>TLO</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3293568\" data-linked=\"10-year Treasury yield tumbles below 2.10%\" data-tweet=\"$TLT $TBT $TMV - 10-year Treasury yield tumbles below 2.10% https://seekingalpha.com/news/3293568-10-year-treasury-yield-tumbles-below-2_10?source=tweet\" data-url=\"https://seekingalpha.com/news/3293568-10-year-treasury-yield-tumbles-below-2_10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293567\" data-ts=\"1504622672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTX\" target=\"_blank\">UTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293567-united-techs-hayes-out-defending-rockwell-deal-says-no-breakup-planned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Tech&#39;s Hayes out defending Rockwell deal, says no breakup planned</a></h4><ul>     <li>United Technologies (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='red'>-3.7%</font>) slumps nearly 4% a day after its <a href=\"https://seekingalpha.com/news/3293417-united-tech-23b-deal-buy-rockwell-collins-updated\" target=\"_blank\">$30B acquisition</a>, including $7B of debt, of Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+0.7%</font>), and UTX&nbsp;CEO Greg Hayes is out <a href=\"https://www.wsj.com/articles/united-tech-ceo-defends-rockwell-deal-1504620748\" target=\"_blank\">defending the deal</a>.</li>     <li>&ldquo;It gives us the opportunity to do things that we wouldn&rsquo;t be able to do on our own,&rdquo; Hayes said in a just-concluded conference call, adding that the combination with ROC will make it easier to meet demand for digital offerings and integrate aircraft systems with benefits such as reducing overall weight.</li>     <li>Hayes also <a href=\"http://www.reuters.com/article/us-rockwell-collins-m-a-utc-divestment/united-tech-not-planning-breakup-after-23-billion-rockwell-deal-idUSKCN1BG1RJ?il=0\" target=\"_blank\">tamps down speculation</a> that UTX would look to sell or spin off other businesses such as Carrier air conditioners or Otis elevators, saying, \"We need the cash flows from all the businesses to help pay down some of this debt&rdquo; and retain an investment-grade credit rating.</li>     <li>The CEO sees $500M in deal synergies by the fourth year, with no changes to the dividend, expecting a 35%-40% payout with suspension of share buybacks for next 3-4 years.</li>     <li>Boeing (<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='red'>-1.2%</font>) is lower, as the deal \"may greatly concern aircraft OEMs such as Airbus and Boeing as they confront an ever increasing proportion of their supply chain controlled by a single supplier,\" says Stephen Perry, managing director at Janes Capital Partners.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293567\" data-linked=\"United Tech&#39;s Hayes out defending Rockwell deal, says no breakup planned\" data-tweet=\"$UTX $UTX $COL - United Tech&#39;s Hayes out defending Rockwell deal, says no breakup planned https://seekingalpha.com/news/3293567-united-techs-hayes-out-defending-rockwell-deal-says-no-breakup-planned?source=tweet\" data-url=\"https://seekingalpha.com/news/3293567-united-techs-hayes-out-defending-rockwell-deal-says-no-breakup-planned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293566\" data-ts=\"1504622510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLLI\" target=\"_blank\">OLLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293566-baml-sees-ollies-bargain-rally-extending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML sees Ollie&#39;s Bargain rally extending</a></h4><ul> <li>Ollie's Bargain Outlet Holdings (<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings'>OLLI</a> <font color='green'>+2.1%</font>) heads higher after Bank of America Merrill Lynch picks coverage back up on the restaurant stock with a <a href=\"https://twitter.com/RatingsNetwork/status/905040851151310853\" target=\"_blank\">Buy rating</a>.</li> <li>BAML's price target of $52 on Ollie's reps +20% upside potential.</li> <li>Shares of Ollie's are already up 53% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293566\" data-linked=\"BAML sees Ollie&#39;s Bargain rally extending\" data-tweet=\"$OLLI - BAML sees Ollie&#39;s Bargain rally extending https://seekingalpha.com/news/3293566-baml-sees-ollies-bargain-rally-extending?source=tweet\" data-url=\"https://seekingalpha.com/news/3293566-baml-sees-ollies-bargain-rally-extending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293563\" data-ts=\"1504621998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWKS\" target=\"_blank\">SWKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293563-citi-upgrades-skyworks-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi upgrades Skyworks to Buy</a></h4><ul><li>        Citi upgrades Skyworks (NASDAQ:<a href='https://seekingalpha.com/symbol/SWKS' title='Skyworks Solutions, Inc.'>SWKS</a>) from Sell to Buy and raises the price target from $90 to $125.</li><li>               Analyst Atif Malik sees the company as an &ldquo;attractive play&rdquo; on increasing RF semiconductor spending for 5G deployments that should pick up in the next three years.&nbsp;</li><li>               Source: <a href=\"https://thefly.com/landingPageNews.php?id=2604284&amp;headline=SWKS-Skyworks-rating-change-\" target=\"_blank\">The Fly</a>&nbsp;</li><li>               Skyworks shares are&nbsp;<font color='green'>up 2.4%</font>.&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3293563\" data-linked=\"Citi upgrades Skyworks to Buy\" data-tweet=\"$SWKS - Citi upgrades Skyworks to Buy https://seekingalpha.com/news/3293563-citi-upgrades-skyworks-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3293563-citi-upgrades-skyworks-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293557\" data-ts=\"1504620895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293557-qualcomm-stay-denied-korean-court\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm stay denied by Korean court</a></h4><ul><li>        Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) <a href=\"https://www.qualcomm.com/news/releases/2017/09/04/qualcomm-stay-appeal-denied-seoul-high-court-absence-irreparable-harm\" target=\"_blank\">announces</a> that the Seoul High Court denied the company&rsquo;s request to hold an order from the country&rsquo;s fair trade regulators.</li><li>               The order requires Qualcomm &ldquo;to engage in good-faith negotiations with chip companies seeking a license and to negotiate possible amendments with current licensees upon request.&rdquo;&nbsp;</li><li>               The Court said the order wouldn&rsquo;t irreparably harm Qualcomm&rsquo;s business, doesn&rsquo;t invalidate existing license agreements, and doesn&rsquo;t prohibit the company from entering patent licenses or limit royalty collections from standard essential partners that abide by the company&rsquo;s fair, reasonable, and non-discriminatory &#40;FRAND&#41; commitments.&nbsp;</li><li>               The stay application, and denial, were separate from the ongoing appeal of the order.&nbsp;</li><li>               Qualcomm shares are&nbsp;<font color='red'>down 1.3%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293144-qualcomm-announces-new-autonomous-vehicle-reference-design-chipset\" target=\"_blank\">Qualcomm announces new autonomous vehicle reference design and chipset</a> (Sept. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293557\" data-linked=\"Qualcomm stay denied by Korean court\" data-tweet=\"$QCOM - Qualcomm stay denied by Korean court https://seekingalpha.com/news/3293557-qualcomm-stay-denied-korean-court?source=tweet\" data-url=\"https://seekingalpha.com/news/3293557-qualcomm-stay-denied-korean-court\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293552\" data-ts=\"1504620308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEL\" target=\"_blank\">CEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293552-cellcom-up-on-strong-tv-subscriber-number-ptnrplus-6_4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellcom up on strong TV subscriber number; PTNR +6.4%</a></h4><ul>   <li>Cellcom Israel (<a href=\"http://seekingalpha.com/symbol/CEL\" target=\"_blank\">CEL</a> <font color='green'>+3.1%</font>) says that about 150,000 households have signed up for its Cellcom TV, which would come to a <a href=\"https://www.globes.co.il/en/article-cellcom-tv-claims-150000-subscribers-1001203643\" target=\"_blank\">market share of 10%</a>.</li>    <li>It had reported 130,000 subs at the half-year mark, which means an additional 20,000 have signed up in two months.</li>    <li>Rival Partner Communications (<a href=\"http://seekingalpha.com/symbol/PTNR\" target=\"_blank\">PTNR</a> <font color='green'>+6.4%</font>) has gotten into the TV market as well, and the competition is lowering prices for television access and inducing more customers to leave Hot and Yes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293552\" data-linked=\"Cellcom up on strong TV subscriber number; PTNR +6.4%\" data-tweet=\"$CEL $CEL $PTNR - Cellcom up on strong TV subscriber number; PTNR +6.4% https://seekingalpha.com/news/3293552-cellcom-up-on-strong-tv-subscriber-number-ptnrplus-6_4?source=tweet\" data-url=\"https://seekingalpha.com/news/3293552-cellcom-up-on-strong-tv-subscriber-number-ptnrplus-6_4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293528\" data-ts=\"1504618047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DAL\" target=\"_blank\">DAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293528-delta-slips-after-traffic-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Delta slips after traffic update</a></h4><ul> <li>Delta Air Lines (NYSE:<a href='https://seekingalpha.com/symbol/DAL' title='Delta Air Lines, Inc.'>DAL</a>) <a href=\"https://seekingalpha.com/pr/16930907-delta-reports-operating-performance-august-2017\" target=\"_blank\">reports</a> revenue miles increased 6.9% in August to 21.619B. Domestic RPMs rose 9.5%.</li> <li>Capacity was up 2.7% to 24.590B available seat miles. Domestic ASMs increased 5.0%.</li> <li>August load factor +350 bps to 87.9%. YTD load factor +150 bps to 85.9%.</li> <li>The company lowers its outlook for Q3 passenger unit revenue to 2% to 3% growth. An operating margin of 16.5% to 17.5% is seen for the quarter vs. 18% to 20% prior view.</li> <li>Shares of Delta <font color='red'>-1.52%</font> premarket to $46.80.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293528\" data-linked=\"Delta slips after traffic update\" data-tweet=\"$DAL - Delta slips after traffic update https://seekingalpha.com/news/3293528-delta-slips-after-traffic-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3293528-delta-slips-after-traffic-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293525\" data-ts=\"1504617817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLPH\" target=\"_blank\">BLPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293525-bellerophons-inopulse-shows-treatment-benefit-in-mid-stage-study-shares-ahead-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellerophon&#39;s INOpulse shows treatment benefit in mid-stage study; shares ahead 15% premarket</a></h4><ul><li>Thinly traded nano cap Bellerophon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a>) jumps&nbsp;<font color='green'>15%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16930769-bellerophon-announces-positive-top-line-phase-2-data-inopulse-treatment-pulmonary\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial assessing INOpulse in patients with pulmonary hypertension with chronic obstructive pulmonary disease (PH-COPD).</li><li>The study was designed to assess the acute effect of pulsed inhaled nitric oxide (iNO) on targeted vasodilation and the chronic effect (four weeks) of iNO on hemodynamics and exercise capacity.</li><li>The acute results showed a statistically valid average increase of 4.2% in blood vessel volume versus baseline in iNO-treated patients and a statistically significant correlation in ventilation-vasodilation, indicating targeted delivery of iNO to the alveoli (tiny air sacs in the lungs).</li><li>The chronic results showed statistically valid increases in six-minute walking distance at both week 2 and week 4 compared to baseline and a statistically significant and clinically meaningful decrease of 19.9% in systolic pulmonary arterial pressure at week 4 compared to baseline.</li><li>No safety signals were observed.</li><li>Clinical development is ongoing. A Phase 3 study in patients with pulmonary arterial hypertension is in process, with top-line data expected in 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293525\" data-linked=\"Bellerophon&#39;s INOpulse shows treatment benefit in mid-stage study; shares ahead 15% premarket\" data-tweet=\"$BLPH - Bellerophon&#39;s INOpulse shows treatment benefit in mid-stage study; shares ahead 15% premarket https://seekingalpha.com/news/3293525-bellerophons-inopulse-shows-treatment-benefit-in-mid-stage-study-shares-ahead-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293525-bellerophons-inopulse-shows-treatment-benefit-in-mid-stage-study-shares-ahead-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293520\" data-ts=\"1504617288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293520-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a> <font color='green'>+121%&nbsp;</font>on the <a href=\"https://seekingalpha.com/news/3293468-insmeds-inhalable-amikacin-successful-late-stage-study-shares-77-percent-premarket\" target=\"_blank\">announcement</a> that inhalable amikacin was successful in late-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='green'>+31%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3293490-cellect-bios-apograft-orphan-drug-u-s-shares-50-percent-preamarket\" target=\"_blank\">announcement&nbsp;</a>that the FDA has designated ApoGraft an Orphan Drug for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.</li>     <li><a href='https://seekingalpha.com/symbol/BLPH' title='Bellerophon Therapeutics'>BLPH</a> <font color='green'>+14%</font>&nbsp;<a href=\"https://seekingalpha.com/pr/16930769-bellerophon-announces-positive-top-line-phase-2-data-inopulse-treatment-pulmonary\" target=\"_blank\">announced </a>positive top line data from a Phase 2 clinical trial evaluating INOpulse in patients with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.</li>     <li><a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='green'>+11%</font>&nbsp;as HAE candidate BCX7353 <a href=\"https://seekingalpha.com/news/3293453-biocryst-pharmas-hae-candidate-bcx7353-successful-mid-stage-study-shares-ahead-11-percent\" target=\"_blank\">successful</a> in mid-stage study.</li>     <li><a href='https://seekingalpha.com/symbol/ORMP' title='Oramed Pharmaceuticals Inc.'>ORMP</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3293467-oramed-announces-successful-meeting-fda-oral-insulin-shares-ahead-15-percent-premarket\" target=\"_blank\">successful</a> meeting with FDA for oral insulin.</li>     <li><a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='green'>+5%</font>&nbsp;on $300M <a href=\"https://seekingalpha.com/pr/16930753-synergy-pharmaceuticals-secures-300-million-debt-financing\" target=\"_blank\">debt financing</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293520\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$INSM $APOP $BLPH - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3293520-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3293520-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293518\" data-ts=\"1504616924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293518-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>&nbsp;<font color='red'>-32%</font>&nbsp;on FDA <a href=\"https://seekingalpha.com/news/3293436-cellectis-29-percent-premarket-fda-hold-studies-ucart123-fatality\" target=\"_blank\">holding</a> on studies of UCART123 after fatality.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3293518\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CLLS - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3293518-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3293518-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293515\" data-ts=\"1504616495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293515-juno-and-bluebird-bio-set-for-pullbacks-after-recent-run-ups-down-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno and bluebird bio set for pullbacks after recent run-ups, both down 2% premarket</a></h4><ul><li>CAR-T developers Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) and bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) are both down 2% premarket on light volume signaling possible profit-taking today after significant rallies. Juno was up almost 70% and bluebird 37%, stoked by Gilead's $11.9B takeout of Kite Pharma.</li><li>Cellectis' stumble with UCART123 is adding pressure as well.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293436-cellectis-29-percent-premarket-fda-hold-studies-ucart123-fatality\" target=\"_blank\">Cellectis down 29% premarket on FDA hold on studies of UCART123 after fatality</a> (Sept. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293515\" data-linked=\"Juno and bluebird bio set for pullbacks after recent run-ups, both down 2% premarket\" data-tweet=\"$JUNO $JUNO $BLUE - Juno and bluebird bio set for pullbacks after recent run-ups, both down 2% premarket https://seekingalpha.com/news/3293515-juno-and-bluebird-bio-set-for-pullbacks-after-recent-run-ups-down-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293515-juno-and-bluebird-bio-set-for-pullbacks-after-recent-run-ups-down-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293511\" data-ts=\"1504615977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MEIP\" target=\"_blank\">MEIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293511-mei-pharma-reports-fy17-results-shares-ahead-14-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MEI Pharma reports FY17 results; shares ahead 14% premarket</a></h4><ul><li>MEI Pharma (<a href='https://seekingalpha.com/symbol/MEIP' title='MEI Pharma, Inc.'>MEIP</a>) <a href=\"https://seekingalpha.com/pr/16930754-mei-pharma-reports-fiscal-year-2017-results\" target=\"_blank\">FY17 results</a>: Revenues: $23.2M; Operating Income: $2.4M; Net Income: $2.7M; EPS: $0.07; Quick Assets: $53.6M (+16.8%).</li><li>No guidance given.</li><li>Shares are up&nbsp;<font color='green'>14%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3293511\" data-linked=\"MEI Pharma reports FY17 results; shares ahead 14% premarket\" data-tweet=\"$MEIP - MEI Pharma reports FY17 results; shares ahead 14% premarket https://seekingalpha.com/news/3293511-mei-pharma-reports-fy17-results-shares-ahead-14-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293511-mei-pharma-reports-fy17-results-shares-ahead-14-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293494\" data-ts=\"1504615014\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LGND\" target=\"_blank\">LGND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293494-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Ligand Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a>) initiated with Buy rating and $150 price target. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Zealand Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZEAL' title='Zealand Pharma'>ZEAL</a>) initiated with Overweight rating and $28 price target by Morgan Stanley. Initiated with Buy rating and $28 price target by Guggenheim. Initiated with Buy rating and $26 price target by Needham. Shares up&nbsp;<font color='green'>2%&nbsp;</font>premarket.</li><li>Alexion Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a>) upgraded to Overweight with a $175 price target by JPMorgan. Shares up&nbsp;<font color='green'>1%</font>&nbsp;premarket.</li><li>Sabra Health (NASDAQ:<a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a>) upgraded to Market Perform with a $23 price target by JMP Securities.</li><li>XOMA (NASDAQ:<a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a>) upgraded to Outperform with a $19 price target by Wedbush. Shares up&nbsp;<font color='green'>9%</font>&nbsp;premarket.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) price target raised to $81 from $73 by Wells Fargo.</li><li>Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) price target raised to $54 from $35 by Wells Fargo.</li><li>bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) price target raised to $158 from $134 by Wells Fargo.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3293494\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$LGND $LGND $ZEAL - Premarket analyst action - healthcare https://seekingalpha.com/news/3293494-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3293494-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293490\" data-ts=\"1504614097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOP\" target=\"_blank\">APOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293490-cellect-bios-apograft-orphan-drug-in-u-s-shares-up-50-preamarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellect Bio&#39;s ApoGraft an Orphan Drug in U.S.; shares up 50% preamarket</a></h4><ul><li>Thinly traded nano cap Cellect Biotechnology Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) is up&nbsp;<font color='green'>50%</font>&nbsp;premarket on higher-than-average volume in response to its <a href=\"https://seekingalpha.com/pr/16930464-fda-grants-orphan-drug-status-cellects-apograft-acute-gvhd-chronic-gvhd\" target=\"_blank\">announcement </a>that the FDA has designated ApoGraft an Orphan Drug for the prevention of acute and chronic graft versus host disease (GvHD) in transplant patients.</li><li>Top-line data from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02828878?term=cellect+biotechnology&amp;rank=2\" target=\"_blank\">Phase 1/2 study</a> should be available in Q1 2018.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li><li>ApoGraft is a stem cell selection process designed to reduce the risk of GvHD. The condition, occurring in as many as 50% of stem cell transplants, can be life-threatening.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3241561-cellect-bio-commences-phase-1-2-study-apograft-prevent-gvhd-shares-35-percent\" target=\"_blank\">Cellect Bio commences Phase 1/2 study of ApoGraft to prevent GvHD; shares up 35%</a> (Feb. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293490\" data-linked=\"Cellect Bio&#39;s ApoGraft an Orphan Drug in U.S.; shares up 50% preamarket\" data-tweet=\"$APOP - Cellect Bio&#39;s ApoGraft an Orphan Drug in U.S.; shares up 50% preamarket https://seekingalpha.com/news/3293490-cellect-bios-apograft-orphan-drug-in-u-s-shares-up-50-preamarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293490-cellect-bios-apograft-orphan-drug-in-u-s-shares-up-50-preamarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293468\" data-ts=\"1504613328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSM\" target=\"_blank\">INSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293468-insmeds-inhalable-amikacin-successful-in-late-stage-study-shares-up-77-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Insmed&#39;s inhalable amikacin successful in late-stage study, shares up 77% premarket</a></h4><ul><li>Insmed (NASDAQ:<a href='https://seekingalpha.com/symbol/INSM' title='Insmed, Inc.'>INSM</a>) is up&nbsp;<font color='green'>77%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16930445-insmed-announces-positive-top-line-results-phase-3-convert-study-alis-amikacin-liposome\" target=\"_blank\">announcement</a> of positive top-line results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02344004?titles=convert&amp;lead=insmed&amp;phase=2&amp;rank=1\" target=\"_blank\">CONVERT</a>, assessing ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-resistant nontuberculous mycobacterial lung disease caused by mycobacterium avium complex &#40;MAC&#41;.</li><li>The study met its primary endpoint of a statistically valid proportion of patients in the ALIS + guideline-based therapy &#40;GBT&#41; cohort achieving culture conversion by month 6 compared to GBT alone.</li><li>Treatment-emergent adverse events were similar between the treatment arms.</li><li>The company plans to pursue accelerated approval in the U.S. where ALIS has Breakthrough Therapy, Fast Track and QIDP status.</li><li>15 months ago, the company withdrew its European marketing application for the product, branded as ARIKAYCE, after a negative vote by the advisory group CHMP citing the need for more efficacy data (the application was based on Phase 2 results).</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3188064-insmed-withdraws-arikayce-marketing-application-europe-shares-13-percent-premarket\" target=\"_blank\">Insmed withdraws Arikayce marketing application in Europe; shares down 13% premarket</a> (June 9, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293468\" data-linked=\"Insmed&#39;s inhalable amikacin successful in late-stage study, shares up 77% premarket\" data-tweet=\"$INSM - Insmed&#39;s inhalable amikacin successful in late-stage study, shares up 77% premarket https://seekingalpha.com/news/3293468-insmeds-inhalable-amikacin-successful-in-late-stage-study-shares-up-77-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293468-insmeds-inhalable-amikacin-successful-in-late-stage-study-shares-up-77-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293467\" data-ts=\"1504612449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORMP\" target=\"_blank\">ORMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293467-oramed-announces-successful-meeting-fda-for-oral-insulin-shares-ahead-15-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oramed announces successful meeting with FDA for oral insulin; shares ahead 15% premarket</a></h4><ul> <li>Oramed Pharmaceuticals&nbsp;(NASDAQ:<a href='https://seekingalpha.com/symbol/ORMP' title='Oramed Pharmaceuticals Inc.'>ORMP</a>) <a href=\"https://seekingalpha.com/pr/16930346-oramed-announces-successful-meeting-fda-oral-insulin\" target=\"_blank\">announces</a> that it has successfully concluded its meeting with the FDA regarding <a href=\"http://www.oramed.com/pipeline/ormd-0801-type-2/\" target=\"_blank\">ORMD-0801</a>, the Company's novel oral insulin formulation.</li><li>The FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801 will be a Biologics License Application &#40;BLA&#41;. Such a pathway would grant a full 12 years of marketing exclusivity for ORMD-0801 if approved. Also, an additional six months of exclusivity can be granted if the product also receives approval for use in pediatric patients.</li> <li>Specific recommendations for clinical trials are also made to provide pivotal data prior to registration.</li><li>At the suggestion of the FDA, Oramed also plans to initiate a three-month trial in patients with type 2 diabetes to evaluate the effect of ORMD-0801 on HbA1c, the main FDA registrational endpoint, later this year.</li><li>Shares are up&nbsp;<font color='green'>15%</font>&nbsp;premarket on light volme.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3293467\" data-linked=\"Oramed announces successful meeting with FDA for oral insulin; shares ahead 15% premarket\" data-tweet=\"$ORMP - Oramed announces successful meeting with FDA for oral insulin; shares ahead 15% premarket https://seekingalpha.com/news/3293467-oramed-announces-successful-meeting-fda-for-oral-insulin-shares-ahead-15-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3293467-oramed-announces-successful-meeting-fda-for-oral-insulin-shares-ahead-15-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293453\" data-ts=\"1504610823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293453-biocryst-pharmas-hae-candidate-bcx7353-successful-in-mid-stage-study-shares-ahead-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst Pharma&#39;s HAE candidate BCX7353 successful in mid-stage study; shares ahead 11% premarket</a></h4><ul><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket, albeit on only 460 shares, in response to its <a href=\"https://seekingalpha.com/pr/16930337-biocryst-announces-positive-results-apexminus-1-phase-2-trial-hae\" target=\"_blank\">announcement </a>of final results from its Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02870972?term=apex-1&amp;rank=1\" target=\"_blank\">APeX-1</a> study assessing BCX7353 as a preventative treatment to reduce the frequency of attacks in patients with hereditary angioedema &#40;HAE&#41;.</li><li>Final results from the three parts of the trial showed treatment with BCX7353 reduced HAE attacks as much as 90% compared to placebo.</li><li>The company plans to meet with U.S. and European regulators in Q4 to finalize the Phase 3 program. Pivotal clinical trials should start in Q1 2018.</li><li>Management will host a conference call today at 9:00 am ET to discuss the data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269874-second-data-pass-biocrysts-mid-stage-study-hae-candidate-bcx7353-reaffirms-treatment-effect\" target=\"_blank\">Second data pass on BioCryst's mid-stage study of HAE candidate BCX7353 reaffirms treatment effect; shares ahead 23% premarket</a> (May 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293453\" data-linked=\"BioCryst Pharma&#39;s HAE candidate BCX7353 successful in mid-stage study; shares ahead 11% premarket\" data-tweet=\"$BCRX - BioCryst Pharma&#39;s HAE candidate BCX7353 successful in mid-stage study; shares ahead 11% premarket https://seekingalpha.com/news/3293453-biocryst-pharmas-hae-candidate-bcx7353-successful-in-mid-stage-study-shares-ahead-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3293453-biocryst-pharmas-hae-candidate-bcx7353-successful-in-mid-stage-study-shares-ahead-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3293436\" data-ts=\"1504608786\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLLS\" target=\"_blank\">CLLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3293436-cellectis-down-29-premarket-on-fda-hold-on-studies-of-ucart123-after-fatality\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectis down 29% premarket on FDA hold on studies of UCART123 after fatality</a></h4><ul><li>Cellectis S.A. (NASDAQ:<a href='https://seekingalpha.com/symbol/CLLS' title='Cellectis S.A.'>CLLS</a>) slumps&nbsp;<font color='red'>29%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1627281/000115752317002441/a51678147ex99_1.htm\" target=\"_blank\">announcement </a>that the FDA has placed its two Phase 1 clinical trials evaluating T-cell therapy UCART123 on clinical hold after a patient died due to cytokine release syndrome &#40;CRS&#41; who also developed grade 4 (life-threatening) capillary leak syndrome.</li><li>The patient was a participant in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03203369?term=UCART123&amp;rank=1\" target=\"_blank\">BPDCN (Blastic Plasmacytoid Cell Neoplasm) study</a> who died nine days after receiving UCART123.</li><li>The first patient treated in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT03190278?term=UCART123&amp;rank=2\" target=\"_blank\">other study</a> in acute myeloid leukemia (same dose) developed grade 3 (severe) CRS and grade 4 capillary leak syndrome that were resolved after a stay in the intensive care unit.</li><li>The Data Safety Monitoring Board has recommended lowering the dose from 6.25 x 10(4) UCART123 cells/kg (from 6.25 x 10(5) cells/kg) and capping preconditioning with cyclophosphamide to a total dose of 4 grams over three days.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3240912-cellectis-gets-green-light-start-clinical-trials-u-s-ucart123-shares-ahead-9-percent-hours\" target=\"_blank\">Cellectis gets green light to start clinical trials in U.S. with UCART123; shares ahead 9% after hours</a> (Feb. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3293436\" data-linked=\"Cellectis down 29% premarket on FDA hold on studies of UCART123 after fatality\" data-tweet=\"$CLLS - Cellectis down 29% premarket on FDA hold on studies of UCART123 after fatality https://seekingalpha.com/news/3293436-cellectis-down-29-premarket-on-fda-hold-on-studies-of-ucart123-after-fatality?source=tweet\" data-url=\"https://seekingalpha.com/news/3293436-cellectis-down-29-premarket-on-fda-hold-on-studies-of-ucart123-after-fatality\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":58,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}